“SummaryA significant myeloprotective effect of melatonin in mice treated with etoposide, cyclophosphamide or carboplatin has been reported.”
“We concluded that, in patients with lung cancer, melatonin given orally at a dose of 40 mg per day for 21 days in the evening, does not protect against the myelotoxic effect of carboplatin and etoposide.”